Table 1.
Pre-transplant characteristics of case and control groups
| Variable | RF (N = 56) | Home (N = 224) | p-value |
|---|---|---|---|
| Age at HCT (years), median (range) | 65 (49 – 77) | 57 (20 – 74) | <0.001 |
| Female | 32 (57.1%) | 94 (42.0%) | 0.036 |
| Disease ALL AML/MDS Amyloidosis Hodgkin Disease Multiple Myeloma MPN (MF, CML, CMML) NHL, B-cell NHL, T-cell Other |
1 (1.8%) 8 (14.3%) 6 (10.7%) 2 (3.6%) 20 (35.7%) 1 (1.8%) 13 (23.2%) 3 (5.4%) 2 (3.6%) |
13 (5.8%) 32 (14.3%) 4 (1.8%) 20 (8.9%) 93 (41.5%) 7 (3.1%) 45 (20.1%) 7 (3.1%) 3 (1.3%) |
0.049 |
| Disease Status at HCT CR1 CR2 or more VGPR PR/Stable Disease Refractory/PD |
14 (25.0%) 6 (10.7%) 8 (14.3%) 21 (37.5%) 7 (12.5%) |
59 (26.3%) 30 (13.4%) 29 (12.9%) 84 (37.5%) 22 (9.8%) |
0.953 |
| Prior HCT First Auto Second Auto Allo after Auto First Allo Second Allo |
34 (60.7%) 5 (8.9%) 4 (7.1%) 13 (23.2%) 0 |
143 (63.8%) 13 (5.8%) 7 (3.1%) 59 (26.3%) 2 (1.0%) |
0.279 |
| Conditioning Dose Myeloablative Non-Myeloablative |
32 (57.1%) 24 (42.9%) |
174 (77.7%) 50 (22.3%) |
< 0.001 |
| HCT-CI, median (range) | 3 (0–10) | 2 (0–9) | <0.001 |
| HCT-CI Risk Group Low (0) Intermediate (1–2) High (3+) |
4 (7.1%) 10 (17.9%) 42 (75.0%) |
44 (19.6%) 73 (32.6%) 107 (47.8%) |
<0.001 |
| Albumin (mg/dL), median (range)* | 3.85 (2.1 – 4.9) | 4 (2.3 – 5.1) | <0.001 |
| ADL Deficits No deficit At least 1 deficit Missing |
47 (83.9%) 3 (5.4%) 6 |
193 (86.2%) 3 (1.3%) 28 |
0.244 |
| Physical Therapy Referral Referred in hospital Referred from clinic No referral |
10 (17.9%) 6 (10.7%) 40 (71.4%) |
18 (8.0%) 18 (8.0%) 188 (83.9%) |
0.076 |
ALL: Acute lymphoblastic leukemia, AML: Acute myeloid leukemia, MDS: Myelodysplastic syndrome, MPN: Myeloproliferative neoplasm, MF: Myelofibrosis, CML: Chronic myeloid leukemia, CMML: Chronic myelomonocytic leukemia, NHL: Non-Hodgkin lymphoma, Other includes plasma cell leukemia, Waldenstrom’s macroglobulinemia, and blastic plasmacytoid dendritic cell neoplasm
*
Albumin followed a non-normal distribution.